基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
After publication of the PACIFIC trial results,immune checkpoint inhibitor-based immunotherapy was included in the treatment algorithm of locally advanced non-small cell lung cancer(NSCLC).The PACIFIC trial demonstrated that 12 mo of durvalumab consolidation therapy after radical-intent platinum doublet chemotherapy with concomitant radiotherapy improved both progression-free survival and overall survival in patients with unresectable stage III NSCLC.This is the first treatment in decades to successfully improve survival in this clinical setting,with manageable toxicity and without deterioration in quality of life.The integration of durvalumab in the management of locally advanced NSCLC accentuates the need for multidisciplinary,coordinated decision-making among lung cancer specialists,bringing new challenges and controversies as well as important changes in clinical work routines.The aim of the present article is to review—from a practical,multidisciplinary perspective—the findings and implications of the PACIFIC trial.We evaluate the immunobiological basis of durvalumab as well as practical aspects related to programmed cell death ligand 1 determination.In addition,we comprehensively assess the efficacy and toxicity data from the PACIFIC trial and discuss the controversies and practical aspects of incorporating durvalumab into routine clinical practice.Finally,we discuss unresolved questions and future challenges.In short,the present document aims to provide clinicians with a practical guide for the application of the PACIFIC regimen in routine clinical practice.
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Deep diving in the PACIFIC:Practical issues in stage III non-small cell lung cancer to avoid shipwreck
来源期刊 世界临床肿瘤学杂志:英文版 学科 医学
关键词 Durvalumab Non-small cell lung cancer PACIFIC Immunotherapy Immune checkpoint inhibitors Anti-programmed cell death ligand 1 Consolidation therapy Unresectable stage III lung cancer
年,卷(期) 2020,(11) 所属期刊栏目
研究方向 页码范围 898-917,I0003
页数 22页 分类号 R73
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2020(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
Durvalumab
Non-small
cell
lung
cancer
PACIFIC
Immunotherapy
Immune
checkpoint
inhibitors
Anti-programmed
cell
death
ligand
1
Consolidation
therapy
Unresectable
stage
III
lung
cancer
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
世界临床肿瘤学杂志:英文版
不定期
2218-4333
北京市朝阳区东四环中路62号楼远洋国际中
出版文献量(篇)
44
总下载数(次)
0
总被引数(次)
0
论文1v1指导